Swiss National Bank bought a new position in Enovis Co. (NYSE:ENOV – Get Rating) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 114,000 shares of the company’s stock, valued at approximately $6,270,000. Swiss National Bank owned about 0.21% of Enovis at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. M&T Bank Corp bought a new stake in shares of Enovis in the second quarter worth about $137,000. Boenning & Scattergood Inc. bought a new stake in shares of Enovis in the second quarter worth about $210,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Enovis in the second quarter worth about $261,000. TAGStone Capital Inc. bought a new stake in shares of Enovis in the second quarter worth about $288,000. Finally, Citadel Investment Advisory Inc. bought a new stake in shares of Enovis in the second quarter worth about $288,000. 89.40% of the stock is owned by institutional investors.
Enovis Price Performance
Shares of NYSE:ENOV opened at $54.99 on Thursday. Enovis Co. has a 1 year low of $43.88 and a 1 year high of $151.63. The business has a 50 day simple moving average of $49.81 and a two-hundred day simple moving average of $55.28. The firm has a market capitalization of $2.98 billion, a PE ratio of 114.56, a price-to-earnings-growth ratio of 1.15 and a beta of 2.03.
Wall Street Analyst Weigh In
Insider Buying and Selling at Enovis
In other Enovis news, EVP Daniel A. Pryor sold 67,421 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $54.58, for a total transaction of $3,679,838.18. Following the completion of the transaction, the executive vice president now owns 75,731 shares in the company, valued at $4,133,397.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 8.30% of the company’s stock.
Enovis Company Profile
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.
- Get a free copy of the StockNews.com research report on Enovis (ENOV)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.